Amit Bar-Or

Summary

Affiliation: McGill University
Country: Canada

Publications

  1. ncbi Immunology of multiple sclerosis
    Amit Bar-Or
    Montreal Neurological Institute, McGill University, Quebec, Montreal, Canada
    Neurol Clin 23:149-75, vii. 2005
  2. pmc Self-antigen tetramers discriminate between myelin autoantibodies to native or denatured protein
    Kevin C O'Connor
    Center for Neurologic Diseases, Brigham and Women s Hospital, 77 Avenue Louis Pasteur, Boston, Massachusetts 02115, USA
    Nat Med 13:211-7. 2007
  3. doi The immunology of multiple sclerosis
    Amit Bar-Or
    Experimental Therapeutics Program, Montreal Neurological Institute, Montreal, Quebec, Canada
    Semin Neurol 28:29-45. 2008
  4. doi Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial
    Amit Bar-Or
    Montreal Neurological Institute, McGill University, Montreal, Quebec, Canada
    Ann Neurol 63:395-400. 2008
  5. pmc Teriflunomide effect on immune response to influenza vaccine in patients with multiple sclerosis
    Amit Bar-Or
    McGill University, Montreal, Quebec, Canada
    Neurology 81:552-8. 2013
  6. ncbi Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the DEFINE study
    Amit Bar-Or
    Montreal Neurological Institute and Hospital, McGill University, Montreal, QC, Canada
    J Neurol 260:2297-305. 2013
  7. doi Abnormal B-cell cytokine responses a trigger of T-cell-mediated disease in MS?
    Amit Bar-Or
    Neuroimmunology Unit, Montreal Neurological Institute and Hospital, McGill University, Montreal Quebec, Canada
    Ann Neurol 67:452-61. 2010
  8. doi Serial combination therapy: is immune modulation in multiple sclerosis enhanced by initial immune suppression?
    A Bar-Or
    Montreal Neurological Institute, Montreal, Quebec, Canada
    Mult Scler 15:959-64. 2009
  9. ncbi Analyses of all matrix metalloproteinase members in leukocytes emphasize monocytes as major inflammatory mediators in multiple sclerosis
    Amit Bar-Or
    Montreal Neurological Institute, Quebec, Canada
    Brain 126:2738-49. 2003
  10. doi Diminished Th17 (not Th1) responses underlie multiple sclerosis disease abrogation after hematopoietic stem cell transplantation
    Peter J Darlington
    Neuroimmunology Unit, Montreal Neurological Institute, McGill University, and Laboratory of Immunology, University of Montreal Hospital Research Centre, Montreal, Quebec, Canada
    Ann Neurol 73:341-54. 2013

Detail Information

Publications86

  1. ncbi Immunology of multiple sclerosis
    Amit Bar-Or
    Montreal Neurological Institute, McGill University, Quebec, Montreal, Canada
    Neurol Clin 23:149-75, vii. 2005
  2. pmc Self-antigen tetramers discriminate between myelin autoantibodies to native or denatured protein
    Kevin C O'Connor
    Center for Neurologic Diseases, Brigham and Women s Hospital, 77 Avenue Louis Pasteur, Boston, Massachusetts 02115, USA
    Nat Med 13:211-7. 2007
    ..MOG-specific autoantibodies were identified in a subset of ADEM but only rarely in adult-onset MS cases, indicating that MOG is a more prominent target antigen in ADEM than MS...
  3. doi The immunology of multiple sclerosis
    Amit Bar-Or
    Experimental Therapeutics Program, Montreal Neurological Institute, Montreal, Quebec, Canada
    Semin Neurol 28:29-45. 2008
    ....
  4. doi Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial
    Amit Bar-Or
    Montreal Neurological Institute, McGill University, Montreal, Quebec, Canada
    Ann Neurol 63:395-400. 2008
    ..Fewer new gadolinium-enhancing or T2 lesions were seen starting from week 4 and through week 72. An apparent reduction in relapses was also observed over the 72 weeks compared with the year before therapy...
  5. pmc Teriflunomide effect on immune response to influenza vaccine in patients with multiple sclerosis
    Amit Bar-Or
    McGill University, Montreal, Quebec, Canada
    Neurology 81:552-8. 2013
    ..To investigate the effect of teriflunomide on the efficacy and safety of seasonal influenza vaccine...
  6. ncbi Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the DEFINE study
    Amit Bar-Or
    Montreal Neurological Institute and Hospital, McGill University, Montreal, QC, Canada
    J Neurol 260:2297-305. 2013
    ..These analyses indicate that treatment with BG-12 is consistently effective across a wide spectrum of patients with relapsing–remitting multiple sclerosis with varied demographic and disease characteristics...
  7. doi Abnormal B-cell cytokine responses a trigger of T-cell-mediated disease in MS?
    Amit Bar-Or
    Neuroimmunology Unit, Montreal Neurological Institute and Hospital, McGill University, Montreal Quebec, Canada
    Ann Neurol 67:452-61. 2010
    ..To study antibody-independent contributions of B cells to inflammatory disease activity, and the immune consequences of B-cell depletion with rituximab, in patients with multiple sclerosis (MS)...
  8. doi Serial combination therapy: is immune modulation in multiple sclerosis enhanced by initial immune suppression?
    A Bar-Or
    Montreal Neurological Institute, Montreal, Quebec, Canada
    Mult Scler 15:959-64. 2009
    ..Recently, brief mitoxantrone induction-chemotherapy followed by immune-modulation with glatiramer acetate (GA) was significantly more effective at reducing multiple sclerosis disease activity than with GA alone...
  9. ncbi Analyses of all matrix metalloproteinase members in leukocytes emphasize monocytes as major inflammatory mediators in multiple sclerosis
    Amit Bar-Or
    Montreal Neurological Institute, Quebec, Canada
    Brain 126:2738-49. 2003
    ....
  10. doi Diminished Th17 (not Th1) responses underlie multiple sclerosis disease abrogation after hematopoietic stem cell transplantation
    Peter J Darlington
    Neuroimmunology Unit, Montreal Neurological Institute, McGill University, and Laboratory of Immunology, University of Montreal Hospital Research Centre, Montreal, Quebec, Canada
    Ann Neurol 73:341-54. 2013
    ..To define changes in phenotype and functional responses of reconstituting T cells in patients with aggressive multiple sclerosis (MS) treated with ablative chemotherapy and autologous hematopoietic stem cell transplantation (HSCT)...
  11. ncbi Inflammatory potential and migratory capacities across human brain endothelial cells of distinct glatiramer acetate-reactive T cells generated in treated multiple sclerosis patients
    Ho Jin Kim
    Department of Neurology, Neuroimmunology Unit, Montreal Neurological Institute, McGill University, Montreal, Quebec, Canada
    Clin Immunol 111:38-46. 2004
    ..Future studies will determine whether this could contribute to variable clinical response to GA therapy...
  12. ncbi Myeloid lineage cells inhibit neurite outgrowth through a myosin II-dependent mechanism
    Madeline Pool
    Department of Neurology and Neurosurgery, Montreal Neurological Institute, 3801 rue University, Montreal, Quebec, Canada H3A 2B4
    J Neuroimmunol 237:101-5. 2011
    ..Our results suggest that in the context of CNS inflammation myeloid cells may limit axonal repair in the CNS via a myosin II-dependent mechanism...
  13. doi Differential responses of human microglia and blood-derived myeloid cells to FTY720
    Bryce A Durafourt
    Neuroimmunology Unit, Montreal Neurological Institute, McGill University, Montreal, Quebec, Canada
    J Neuroimmunol 230:10-6. 2011
    ..Despite similar receptor expression patterns, the distinct myeloid cell populations present in the human CNS, under steady-state or inflammatory conditions, exhibit differential responses to FTY720...
  14. ncbi Induction of antigen-specific tolerance in multiple sclerosis after immunization with DNA encoding myelin basic protein in a randomized, placebo-controlled phase 1/2 trial
    Amit Bar-Or
    Montreal Neurological Institute, Montreal, Quebec, Canada
    Arch Neurol 64:1407-15. 2007
    ..To assess safety and immune modulation by BHT-3009, a tolerizing DNA vaccine encoding full-length human myelin basic protein, in patients with multiple sclerosis (MS)...
  15. pmc Dual effects of daily FTY720 on human astrocytes in vitro: relevance for neuroinflammation
    Celina Wu
    Montreal Neurological Institute, McGill University, 3801 University St, Montreal QC H3A 2B4, Canada
    J Neuroinflammation 10:41. 2013
    ..For the function-inducing responses, we measured inhibition of intracellular calcium release stimulated by the proinflammatory cytokine, interleukin (IL)-1β...
  16. doi Reduction of the peripheral blood CD56(bright) NK lymphocyte subset in FTY720-treated multiple sclerosis patients
    Trina A Johnson
    Neuroimmunology Unit, Montreal Neurological Institute, McGill University, Montreal, Quebec H3A 2B4, Canada
    J Immunol 187:570-9. 2011
    ..Subset alterations and function of NK cell populations will need to be considered as part of assessing overall immunosurveillance capacity of patients with MS who will receive sustained FTY720 therapy...
  17. doi Reciprocal Th1 and Th17 regulation by mesenchymal stem cells: Implication for multiple sclerosis
    Peter J Darlington
    Neuroimmunology Unit, Montreal Neurological Institute, Montreal, Quebec, Canada
    Ann Neurol 68:540-5. 2010
    ..These findings underscore the importance of further preclinical work and immune-monitoring to define hMSC effects on disease-relevant immune responses under variable conditions...
  18. doi Elevated serum inflammatory markers in post-poliomyelitis syndrome
    Christopher B Fordyce
    Department of Neurology and Neurosurgery, Montreal Neurological Institute and Hospital, Montreal, Quebec, Canada
    J Neurol Sci 271:80-6. 2008
    ..The cause of PPS is unknown, but abnormal inflammatory responses have been implicated in several small studies...
  19. ncbi Distinct effector cytokine profiles of memory and naive human B cell subsets and implication in multiple sclerosis
    Martin Duddy
    Neuroimmunology Unit, Montreal Neurological Institute, McGill University, Montreal, and Department of Neurology, Ottawa General Hospital, Canada
    J Immunol 178:6092-9. 2007
    ..Our findings are of particular relevance at a time when B cell directed therapies are being applied to clinical trials of several autoimmune diseases...
  20. ncbi Type 2 monocyte and microglia differentiation mediated by glatiramer acetate therapy in patients with multiple sclerosis
    Ho Jin Kim
    Neuroimmunology Unit, Montreal Neurological Institute, McGill University, Montreal, Quebec, Canada
    J Immunol 172:7144-53. 2004
    ..In addition to extending insights into the therapeutic mode of action of GA, our findings revisit the concept of bystander suppression and underscore the potential of APCs as attractive targets for therapeutic immune modulation...
  21. doi Reconstitution of circulating lymphocyte counts in FTY720-treated MS patients
    Trina A Johnson
    Neuroimmunology Unit, Montreal Neurological Institute, McGill University, Montreal, Quebec, Canada
    Clin Immunol 137:15-20. 2010
    ..This is relevant for clinical decisions regarding management of patients using this therapy and for introducing alternate therapies...
  22. ncbi miR-155 as a multiple sclerosis-relevant regulator of myeloid cell polarization
    Craig S Moore
    Neuroimmunology Unit, Department of Neurology and Neurosurgery, Montreal Neurological Institute and Hospital, McGill University, Montreal, Quebec
    Ann Neurol 74:709-20. 2013
    ..To define the functional significance of increased miR-155 expression in myeloid cells in multiple sclerosis (MS)...
  23. ncbi Natalizumab effects on immune cell responses in multiple sclerosis
    Masaaki Niino
    Department of Neurology and Neurosurgery, Montreal Neurological Institute, McGill University, Quebec, Canada
    Ann Neurol 59:748-54. 2006
    ..Our objective was to study in vivo biological effects of natalizumab on immune cell phenotype and function in multiple sclerosis (MS) patients...
  24. doi Myelin regulates immune cell adhesion and motility
    Madeline Pool
    Department of Neurology and Neurosurgery, Montreal Neurological Institute, 3801 rue University, Montreal, Quebec, Canada H3A 2B4
    Exp Neurol 217:371-7. 2009
    ..We conclude that NgR1 alters the motility of immune cells exposed to myelin and may thus impact their behaviour within the CNS, particularly under conditions when immune cell activation is heightened...
  25. doi Neurite outgrowth is differentially impacted by distinct immune cell subsets
    Madeline Pool
    Department of Neurology and Neurosurgery, Montreal Neurological Institute, 3801 rue University, Montreal, Quebec, Canada, H3A 2B4
    Mol Cell Neurosci 49:68-76. 2012
    ..Our findings describe heterogeneous effects of individual immune cell subsets on neuronal growth and offer important insights into the cellular and molecular mechanisms that may impact axonal repair in inflammatory CNS conditions...
  26. ncbi Dendritic cell differentiation signals induce anti-inflammatory properties in human adult microglia
    Caroline Lambert
    Physiology Department, Montreal Neurology Institute, McGill University, Montreal, Quebec, Canada
    J Immunol 181:8288-97. 2008
    ..Moreover, such treatment, especially of adult microglia, induces functional responses that could promote an antiinflammatory environment in the CNS...
  27. pmc Naive CD4 T-cell activation identifies MS patients having rapid transition to progressive MS
    Evelyn Zastepa
    From Neuroscience E Z, L F G, Department of Pathology D G H, and McGill Centre for Bioinformatics M H, McGill University, Montreal Neurology J A, A B O, Y L, Montreal Neurological Hospital, Montreal, Canada and Neurology S B, UCSF, San Francisco, CA
    Neurology 82:681-90. 2014
    ..Our objective was to determine whether altered naive CD4 T-cell biology contributes to development of disease progression in secondary progressive multiple sclerosis (SPMS)...
  28. pmc Basis for fluctuations in lymphocyte counts in fingolimod-treated patients with multiple sclerosis
    David Henault
    From the Neuroimmunology Unit, Montreal Neurological Institute, McGill University, Canada
    Neurology 81:1768-72. 2013
    ....
  29. doi Implication of perturbed axoglial apparatus in early pediatric multiple sclerosis
    Ajit Singh Dhaunchak
    Department of Neurology and Neurosurgery, Montreal Neurological Institute and Hospital, McGill University and McGill University Health Centre, Quebec, Canada
    Ann Neurol 71:601-13. 2012
    ..However, multiple molecules that localize to the node of Ranvier and the surrounding axoglial apparatus membrane were implicated, indicating perturbed axon-glial interactions in those children destined for diagnosis of MS...
  30. doi Distinct properties of circulating CD8+ T cells in FTY720-treated patients with multiple sclerosis
    Trina A Johnson
    Montreal Neurological Institute, QC, Canada
    Arch Neurol 67:1449-55. 2010
    ..To define the capacity of peripheral blood CD8(+) T cells from patients with multiple sclerosis (MS) receiving fingolimod (FTY720) to migrate in response to chemokines that contribute to trafficking into the central nervous system...
  31. doi Innate immune-mediated neuronal injury consequent to loss of astrocytes
    Peter J Darlington
    Neuroimmunology Unit, Montreal Neurological Institute, McGill University, Montreal, Quebec, Canada
    J Neuropathol Exp Neurol 67:590-9. 2008
    ..These data suggest that non-major histocompatibility complex-restricted immune effector cells may contribute to neuron loss in neuroinflammatory disorders indirectly through injury of glia...
  32. ncbi Emerging multiple sclerosis disease-modifying therapies
    Paul S Giacomini
    Multiple Sclerosis Clinic, Montreal Neurological Institute and Hospital, McGill University Health Centre, Quebec, Canada
    Curr Opin Neurol 22:226-32. 2009
    ..We focus on emerging therapies for the treatment of multiple sclerosis (MS) whose progress through late-phase clinical trials has furthered our understanding of MS pathophysiology...
  33. doi Comparison of polarization properties of human adult microglia and blood-derived macrophages
    Bryce A Durafourt
    Neuroimmunology Unit, Montreal Neurological Institute, McGill University, Montreal, Quebec, Canada
    Glia 60:717-27. 2012
    ..Our findings delineate distinctive properties of microglia compared with exogenous myeloid cells in response to signals derived from an inflammatory environment in the CNS...
  34. ncbi Human immune studies in multiple sclerosis
    Amit Bar-Or
    Program in Experimental Therapeutics, Clinical Research Unit, Montreal Neurological Institute and McGill University, Quebec, Canada
    Adv Neurol 98:91-109. 2006
  35. doi Polysomnographic measures of disturbed sleep are associated with reduced quality of life in multiple sclerosis
    Daria A Trojan
    Department of Neurology and Neurosurgery, Montreal Neurological Institute and Hospital, McGill University Health Centre, 3801 University St, Montreal, Quebec, Canada
    J Neurol Sci 316:158-63. 2012
    ..The relationship of objective sleep parameters with health-related quality of life (HRQoL) in multiple sclerosis (MS) has not been studied...
  36. pmc Clinical and MRI activity as determinants of sample size for pediatric multiple sclerosis trials
    Leonard H Verhey
    From the Pediatric Demyelinating Disease Program L H V, Program in Neuroscience and Mental Health, The Hospital for Sick Children, University of Toronto, Canada Biostatistics Unit A S, M P S, Department of Health Sciences, University of Genova, Italy Department of Neurology and Neurosurgery D L A, A B O, Montreal Neurological Institute and Hospital, McGill University, Montreal Department of Neurology and Division of Medical Genetics A D S, University of British Columbia, Vancouver Departments of Internal Medicine and Community Health Sciences R A M, Winnipeg Health Sciences Centre, University of Manitoba, Winnipeg, Canada and Division of Neurology B B, Department of Pediatrics, The Children s Hospital of Philadelphia, University of Pennsylvania
    Neurology 81:1215-21. 2013
    ..To estimate sample sizes for pediatric multiple sclerosis (MS) trials using new T2 lesion count, annualized relapse rate (ARR), and time to first relapse (TTFR) endpoints...
  37. doi Reduced thymic output and peripheral naïve CD4 T-cell alterations in primary progressive multiple sclerosis (PPMS)
    David G Haegert
    Department of Pathology, McGill University, 3775 Rue University, Montreal, QC, Canada H3A 2B4
    J Neuroimmunol 233:233-9. 2011
    ..We conclude PPMS patients have peripheral immune alterations related to reduced thymic output...
  38. ncbi Potential for interferon beta-induced serum antibodies in multiple sclerosis to inhibit endogenous interferon-regulated chemokine/cytokine responses within the central nervous system
    Aaron M Shapiro
    Neuroimmunology Unit and Multiple Sclerosis Clinic, Montreal Neurological Institute, 3801 University Street, Montreal, Quebec
    Arch Neurol 63:1296-9. 2006
    ..Although systemic interferon beta does not access the central nervous system, titers of serum NAbs may be sufficient that some will access the central nervous system...
  39. pmc MicroRNA dysregulation in multiple sclerosis
    Omar de Faria Jr
    Department of Neurology and Neurosurgery, The Montreal Neurological Institute and Hospital, McGill University Health Centre, McGill University Montreal, QC, Canada Program in NeuroEngineering, McGill University Montreal, QC, Canada
    Front Genet 3:311. 2012
    ..Herein, we review miRNA signatures reported in CNS tissue and immune cells of MS patients and consider how altered miRNA expression may influence MS pathology...
  40. ncbi Determinants of human B cell migration across brain endothelial cells
    Andrea Alter
    Neuroimmunology Unit, Montreal Neurological Institute, Montreal, Quebec, Canada
    J Immunol 170:4497-505. 2003
    ....
  41. doi From bench to MS bedside: challenges translating biomarker discovery to clinical practice
    Sathyanath Rajasekharan
    McGill Centre for Biomedical Innovation, McGill University, Montreal, Quebec, Canada H3A 2R7
    J Neuroimmunol 248:66-72. 2012
    ..We will define the types of biomarkers that would be relevant for MS, identify their ideal attributes, and then discuss individual challenges and strategies to overcome them...
  42. pmc Harnessing the therapeutic potential of mesenchymal stem cells in multiple sclerosis
    Peter J Darlington
    Neuroimmunology Unit, Montreal Neurological Institute, McGill University, Montreal, QC, Canada
    Expert Rev Neurother 11:1295-303. 2011
    ..This article will focus on the theoretical and practical issues relevant to considerations of MSC therapy in the context of MS...
  43. ncbi Roles of immunoglobulins and B cells in multiple sclerosis: from pathogenesis to treatment
    Jack Antel
    Neuroimmunology Unit, Montreal Neurological Institute and McGill University, 3801 University Street, Room 111, Montreal, Quebec, Canada H3A2B4
    J Neuroimmunol 180:3-8. 2006
    ..This presentation considers what roles Ig and/or B cells can play in mediating or regulating disease-relevant immune responses in MS. A timely corollary is whether B cell/Ig-directed therapeutic strategies can be effective in MS...
  44. ncbi Microglia and multiple sclerosis
    Carolyn Jack
    Neuroimmunology Unit, Montreal Neurological Institute, Montreal, Quebec, Canada
    J Neurosci Res 81:363-73. 2005
    ..A therapeutic challenge is to modulate the dynamic properties of microglia/macrophages so as to limit potentially damaging innate responses, to protect the CNS from injury, and to promote local recovery...
  45. doi A proteome map of axoglial specializations isolated and purified from human central nervous system
    Ajit S Dhaunchak
    The Montreal Neurological Institute and Hospital, McGill University, Department of Neurology and Neurosurgery, Montreal H3A2B4, Canada
    Glia 58:1949-60. 2010
    ....
  46. ncbi B-cell subsets: cellular interactions and relevance in multiple sclerosis
    Claudia J Calder
    Post Doctoral Research Fellow, Montreal Neurological Institute, Claudia J Calder, Neuroimmunology Unit, 3801 University Street, Montreal, Quebec, H3A 2B4 Canada
    Expert Rev Clin Immunol 3:73-83. 2007
    ..The topic is of particular interest at a time that B-cell-directed therapies are being evaluated for this and other autoimmune diseases...
  47. ncbi Fatigue in multiple sclerosis: association with disease-related, behavioural and psychosocial factors
    D A Trojan
    Department of Neurology and Neurosurgery, Montreal Neurological Institute and Hospital, McGill University Health Centre, McGill University, Montreal, Quebec, Canada
    Mult Scler 13:985-95. 2007
    ..Correlates of general and physical fatigue are disease-related, behavioural and psychosocial factors. Correlates of mental fatigue are psychosocial factors. Potentially modifiable factors account for a considerable portion of fatigue...
  48. ncbi Immunological memory: contribution of memory B cells expressing costimulatory molecules in the resting state
    A Bar-Or
    Center for Neurologic Diseases, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    J Immunol 167:5669-77. 2001
    ..Finally, these studies extend recent observations in the murine system and highlight the phenotypic and functional diversity that exists within the human B cell memory compartment...
  49. doi Lesion distribution in children with clinically isolated syndromes
    Rezwan Ghassemi
    Montreal Neurological Institute, McGill University, Montreal, Quebec
    Ann Neurol 63:401-5. 2008
    ....
  50. pmc Regulation of miRNA 219 and miRNA Clusters 338 and 17-92 in Oligodendrocytes
    Omar de Faria
    Department of Neurology and Neurosurgery, Montreal Neurological Institute and Hospital, McGill University Health Centre, McGill University Montreal, QC, Canada
    Front Genet 3:46. 2012
    ..Thus, these miRs should be recognized as potential therapeutic targets in demyelinating disorders...
  51. ncbi NeuriteTracer: a novel ImageJ plugin for automated quantification of neurite outgrowth
    Madeline Pool
    Department of Neurology and Neurosurgery, Montreal Neurological Institute, BT 109, 3801 rue University, Montreal, Quebec, Canada H3A 2B4
    J Neurosci Methods 168:134-9. 2008
    ..Our plugin is an attractive alternative to existing tracing tools because it is fully automated and ready for use within a freely accessible imaging program...
  52. doi Targeting progressive neuroaxonal injury: lessons from multiple sclerosis
    Amit Bar-Or
    Department of Neurology and Neurosurgery and Microbiology and Immunology, McGill University, Neuroimmunology Unit, Montreal, QC, Canada
    CNS Drugs 25:783-99. 2011
    ..The use of MS as a clinical model to study modulation of neuroaxonal injury in the brain could have direct implications for the development of treatment strategies in neurodegenerative diseases such as AD, PD and ALS...
  53. ncbi Distinct profiles of human B cell effector cytokines: a role in immune regulation?
    Martin E Duddy
    Neuroimmunology Unit, Montreal Neurological Institute and McGill University, Montreal, Quebec, Canada
    J Immunol 172:3422-7. 2004
    ..We thus describe a novel paradigm of reciprocal regulation of B cell effector cytokines, and ascribe active roles for human B cells in either promoting or suppressing local immune responses through context-dependent cytokine production...
  54. doi Risk genes associated with pediatric-onset MS but not with monophasic acquired CNS demyelination
    E Daniëlle van Pelt
    From the Departments of Neurology E D v P, J Y M, I A K, R F N, C E C B, R Q H and Epidemiology S K, L B, C J, C M v D, Erasmus MC, Rotterdam, the Netherlands the Departments of Pediatrics and Neurology N M, Yale School of Medicine, New Haven, CT the Department of Epidemiology C J, Emory University, Atlanta, GA the Department of Neurology B B, Children s Hospital of Philadelphia, PA the Division of Neurology B B, Hospital for Sick Children and University of Toronto and Montreal Neurological Institute A B O, McGill University, Canada
    Neurology 81:1996-2001. 2013
    ....
  55. ncbi 8th international congress of neuroimmunology
    Jack Antel
    Neuroimmunology Unit, Montreal Neurologic Institute, McGill University, Montreal H3A2B4, Quebec, Canada
    J Neuroimmunol 185:6-8. 2007
  56. pmc Epstein-Barr virus in oral shedding of children with multiple sclerosis
    Carmen Yea
    From Neuroscience and Mental Health, Research Institute C Y, The Hospital for Sick Children, Toronto the Department of Microbiology, Immunology, and Infectious Diseases R T, University of Calgary the Provincial Public Health Laboratory of Alberta R T, Calgary the National Microbiology Laboratory P C, G W, Public Health Agency of Canada, Winnipeg the Department of Internal Medicine R A M, University of Manitoba, Winnipeg the Experimental Therapeutics Program A B O, Montreal Neurological Institute, McGill University, Montreal, Canada and the Division of Neurology B B, The Children s Hospital of Philadelphia, PA
    Neurology 81:1392-9. 2013
    ..To investigate Epstein-Barr virus (EBV) oral shedding frequency and EBV genetic diversity in pediatric patients with multiple sclerosis (MS)...
  57. doi Epidural blood patch in a patient with multiple sclerosis: is it safe?
    Vesselina Koeva
    Department of Anesthesia, McGill University, Montreal, QC, Canada
    Can J Anaesth 60:479-83. 2013
    ..While peridural pressure changes were not measured, we attempted to quantify any pressure-induced interference with axonal conduction by measuring changes in somatosensory evoked responses...
  58. doi Laquinimod in multiple sclerosis
    Paul S Giacomini
    Department of Neurology and Neurosurgery, McGill University, Montreal, Quebec, Canada
    Clin Immunol 142:38-43. 2012
    ..If phase III studies confirm clinical efficacy and safety, laquinimod would represent a welcome new option in the treatment of multiple sclerosis...
  59. ncbi Neuromyelitis optica with hypothalamic involvement
    Alexandre Y Poppe
    McGill University Health Centre, The Montreal Neurological Institute and Hospital, 3801 University Street, Montreal, Quebec, Canada
    Mult Scler 11:617-21. 2005
    ..We propose that the currently accepted criteria for the diagnosis of NMO could be revisited to recognize the possibility of lesions developing within hypothalamic structures...
  60. ncbi Do myelin-directed antibodies predict multiple sclerosis?
    Jack P Antel
    Montreal Neurological Institute, McGill University, Montreal
    N Engl J Med 349:107-9. 2003
  61. ncbi Differential effects of Th1 and Th2 lymphocyte supernatants on human microglia
    Rosanne Seguin
    Neuroimmunology Unit, Montreal Neurological Institute, McGill University, Quebec, Canada
    Glia 42:36-45. 2003
    ....
  62. pmc Teriflunomide and its mechanism of action in multiple sclerosis
    Amit Bar-Or
    Department of Neurology and Neurosurgery, Montreal Neurological Institute, McGill University, Montreal, Canada
    Drugs 74:659-74. 2014
    ..Taken together, these data demonstrate how teriflunomide acts as a selective immune therapy for patients with MS. ..
  63. doi A condensed performance-validation strategy for multiplex detection kits used in studies of human clinical samples
    Chahrazed Belabani
    Experimental Therapeutics Program, Montreal Neurological Institute, McGill University, Montreal, QC, Canada
    J Immunol Methods 387:1-10. 2013
    ..Our findings confirm the importance of validating the performance of commercial multiplex kits and provide a practical and cost-effective approach that can be readily implemented in both academic and translational laboratory settings...
  64. doi Treatment of multiple sclerosis with anti-CD20 antibodies
    Barbara Barun
    Neuroimmunology Unit and Experimental Therapeutics Program, Montreal Neurological Institute and Hospital, McGill University Hospital Centre Montreal, Quebec, Canada
    Clin Immunol 142:31-7. 2012
    ....
  65. ncbi Fatigue in post-poliomyelitis syndrome: association with disease-related, behavioral, and psychosocial factors
    Daria A Trojan
    Department of Neurology and Neurosurgery, Montreal Neurological Institute and Hospital, McGill University Health Centre, McGill University, 3801 University St, Montreal, Quebec, H3A 2B4, Canada
    PM R 1:442-9. 2009
    ....
  66. doi Antigen-specific therapies in multiple sclerosis
    Paul S Giacomini
    McGill University, Montreal Neurological Hospital and Institute, Multiple Sclerosis Clinic, McConnell Brain Imaging Centre, Department of Neurology and Neurosurgery, 3801, University St, Room WB 327, Montreal, QUE H3A 2B4, Canada
    Expert Opin Emerg Drugs 14:551-60. 2009
    ..If found to be effective, antigen-specific therapies in MS hold the promise of selectively targeting pathogenic effector cells, while leaving the rest of immune system undisturbed...
  67. doi Clinical immunology of the sphingosine 1-phosphate receptor modulator fingolimod (FTY720) in multiple sclerosis
    M Mehling
    Department of Neurology, University Hospital, Basel, Switzerland
    Neurology 76:S20-7. 2011
    ....
  68. doi B-cell depletion with rituximab in relapsing-remitting multiple sclerosis
    Stephen L Hauser
    Department of Neurology, University of California at San Francisco, San Francisco, CA 94143 0114, USA
    N Engl J Med 358:676-88. 2008
    ..There is increasing evidence that B lymphocytes are involved in the pathogenesis of multiple sclerosis, and they may be a therapeutic target. Rituximab, a monoclonal antibody, selectively targets and depletes CD20+ B lymphocytes...
  69. ncbi Quantitative analysis of human endogenous retrovirus-W env in neuroinflammatory diseases
    Joseph M Antony
    Department of Clinical Neurosciences, University of Calgary, Calgary, AB, Canada
    AIDS Res Hum Retroviruses 22:1253-9. 2006
    ..033 log10/ml versus MS: 2.9 log10/ml). These observations emphasize the selective induction of syncytin-1 in brain tissue of MS patients but also illustrate the complex dynamics of this retroelement in neuroinflammatory processes...
  70. ncbi Patient and community preferences for treatments and health states in multiple sclerosis
    Lisa A Prosser
    Department of Ambulatory Care and Prevention, Harvard Medical School and Harvard Pilgrim Health Care, Boston, MA 02215, USA
    Mult Scler 9:311-9. 2003
    ..To examine preferences for treatments and health states for patients with relapsing-remitting MS and members of the community...
  71. ncbi Myelin basic protein-reactive autoantibodies in the serum and cerebrospinal fluid of multiple sclerosis patients are characterized by low-affinity interactions
    Kevin C O'Connor
    Laboratory of Molecular Immunology, Harvard Medical School, Center for Neurologic Disease, Brigham and Women s Hospital, Harvard Institutes of Medicine, Rm 780, 77 Avenue Louis Pasteur, Boston, MA 02115, USA
    J Neuroimmunol 136:140-8. 2003
    ..These results indicate that the humoral response in patients with MS does not include moderate- or high-affinity autoantibodies to MBP...
  72. ncbi CTLA-4 dysregulation in the activation of myelin basic protein reactive T cells may distinguish patients with multiple sclerosis from healthy controls
    Enedina M L Oliveira
    Laboratory of Molecular and Cellular Immunology, Center for Neurologic Diseases, Brigham and Women s Hospital and Harvard Medical School, Boston, MA, USA
    J Autoimmun 20:71-81. 2003
    ..Understanding how co-stimulatory signals may be dysregulated in patients with MS is important at a time when targeting of these pathways is being developed...
  73. ncbi Multiple sclerosis in children: clinical diagnosis, therapeutic strategies, and future directions
    Brenda Banwell
    Department of Paediatrics, Division of Neurology, The Hospital for Sick Children, University of Toronto, Toronto, Canada
    Lancet Neurol 6:887-902. 2007
    ..Understanding the immunological consequences of these putative exposures will shed light on the early pathological changes in MS...
  74. doi Cross-reactivity between epidemiology and immunology in multiple sclerosis
    Amit Bar-Or
    Neurology 71:1132-3. 2008
  75. ncbi The relationship between risk attitude and treatment choice in patients with relapsing-remitting multiple sclerosis
    Lisa A Prosser
    Department of Ambulatory Care and Prevention, Harvard Medical School, 133 Brookline Ave, 6th Floor, Boston, MA 02215, USA
    Med Decis Making 22:506-13. 2002
    ....
  76. pmc Increased T cell reactivity to amyloid beta protein in older humans and patients with Alzheimer disease
    Alon Monsonego
    Center for Neurologic Diseases, Harvard Medical School and Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    J Clin Invest 112:415-22. 2003
    ....
  77. ncbi Functional consequences of neuromyelitis optica-IgG astrocyte interactions on blood-brain barrier permeability and granulocyte recruitment
    Thierry Vincent
    Laboratoire d Immunologie, Hôpital Saint Eloi CHU Montpellier, Montpellier, France
    J Immunol 181:5730-7. 2008
    ..Our study highlights important functional roles for NMO-IgG that could account for pathological lesions and BBB dysfunction observed in NMO...
  78. ncbi Pharmacological treatment of early multiple sclerosis
    Olaf Stuve
    Neurology Section, VA North Texas Health Care System, Medical Service, Dallas, Texas 75216, USA
    Drugs 68:73-83. 2008
    ....
  79. ncbi Altered CD4+/CD8+ T-cell ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis
    Olaf Stuve
    Department of Neurology, University of Texas Southwestern Medical Center at Dallas, USA
    Arch Neurol 63:1383-7. 2006
    ....
  80. ncbi Microglial expression of the B7 family member B7 homolog 1 confers strong immune inhibition: implications for immune responses and autoimmunity in the CNS
    Tim Magnus
    Department of Neurology, University of Homburg, D 66424 Homburg, Germany
    J Neurosci 25:2537-46. 2005
    ..Together, our data propose microglial B7-H1 as an important immune inhibitory molecule capable of downregulating T-cell activation in the CNS and thus confining immunopathological damage...
  81. ncbi Additive effect of the combination of glatiramer acetate and minocycline in a model of MS
    Fabrizio Giuliani
    Department of Clinical Neurosciences, University of Calgary, Calgary, Alberta, Canada
    J Neuroimmunol 158:213-21. 2005
    ..This combination resulted in a significant reduction of disease severity and disease burden with attenuation of the inflammation, axonal loss and demyelination...
  82. ncbi What do we know about the mechanism of action of disease-modifying treatments in MS?
    Hans Peter Hartung
    Heinrich Heine University, Moorenstrasse 4, 40225 Duesseldorf, Germnay
    J Neurol 251:v12-v29. 2004
    ..Further increases in our understanding of the pathogenesis of MS are likely to assist in the identification of new targets for disease-modifying therapies and in the optimisation of current treatments....
  83. ncbi Cost-effectiveness of interferon beta-1a, interferon beta-1b, and glatiramer acetate in newly diagnosed non-primary progressive multiple sclerosis
    Lisa A Prosser
    Department of Ambulatory Care and Prevention, Harvard Medical School and Harvard Pilgrim Health Care, Boston, MA 02215, USA
    Value Health 7:554-68. 2004
    ..To perform a cost-effectiveness analysis of three immunomodulatory treatments for newly diagnosed nonprimary progressive MS: interferon beta-1a, interferon beta-1b, and glatiramer acetate...
  84. ncbi Clinical features and viral serologies in children with multiple sclerosis: a multinational observational study
    Brenda Banwell
    Division of Neurology, The Hospital for Sick Children, University of Toronto, ON, Canada
    Lancet Neurol 6:773-81. 2007
    ..Our aim was to determine some of these characteristics in children with MS...
  85. ncbi Abnormal T-cell reactivities in childhood inflammatory demyelinating disease and type 1 diabetes
    Brenda Banwell
    Division of Neurology, Department of Pediatrics and the Research Institute, The Hospital for Sick Children, University of Toronto, Toronto, Canada
    Ann Neurol 63:98-111. 2008
    ..Our objectives were to determine the presence, pattern, and specificity of abnormal T-cell reactivities to such antigens in the earliest stages of the multiple sclerosis process...
  86. ncbi Expression of the immune-tolerogenic major histocompatibility molecule HLA-G in multiple sclerosis: implications for CNS immunity
    Heinz Wiendl
    Department of General Neurology, Hertie Institute for Clinical Brain Research, University of Tubingen, Tubingen, Germany
    Brain 128:2689-704. 2005
    ..This pathway may act as an inhibitory feedback aimed to downregulate the deleterious effects of T-cell infiltration in neuroinflammation...